Table 1 Baseline patient characteristics
Placebo N = 93 | Etoricoxib 90 mg N = 103 | Etoricoxib 120 mg N = 92 | Naproxen 1000 mg N = 99 | |
Age (years), mean (SD) | 43.7 (12.1) | 43.1 (12.1) | 42.5 (12.0) | 45.0 (11.4) |
Female (%) | 20.4 | 26.2 | 21.7 | 20.2 |
History of iritis (%) | 33.3 | 37.9 | 31.5 | 31.3 |
History of chronic peripheral arthritis (%) | 39.8 | 39.8 | 39.1 | 41.4 |
History of corticosteroid use (%) | 32.3 | 23.3 | 23.9 | 22.2 |
Concomitant DMARD use (%)* | 19.4 | 26.2 | 19.6 | 23.2 |
Baseline BASDAI (100-mm VAS), mean (SD) | 54.1 (27.0) | 56.9 (22.5) | 55.2 (25.1) | 54.1 (23.2) |
Baseline spine pain (100-mm VAS), mean (SD) | 77.2 (15.2) | 78.0 (13.9) | 78.0 (14.2) | 77.2 (16.5) |